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Abstract
Context: Diagnosis of human brucellosis still challenges clinicians and scientists with several considerable aspects, particularly in
endemic countries. The current study aimed at reviewing laboratory tests in the diagnosis of human brucellosis.
Evidence Acquisition: A literature search was conducted in PubMed, Scopus, Thompson Reuters, and Mesh databases using key-
words for articles published until December 2018. Seventy studies were selected for data collection.
Results: The current inclusive review included information about the currently used advanced diagnostic tests to confirm the de-
tection of human brucellosis.
Conclusions: The article reviewed the methods for the diagnosis of human brucellosis and summarized developments for the fu-
ture.
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1. Context
Brucellosis is a zoonotic disease, endemic in many
parts of the world especially the Middle East, South and
Central Asia, Mediterranean region, Europe, North and
East Africa, and Latin America with over half a million new
cases annually (1-3). Clinical management of brucellosis is
one of the most challenging obstacles due to a high rate of
failure in treatment and subsequent relapse (4, 5). Defini-
tive diagnosis of brucellosis needs comprehensive evalu-
ation of the living conditions of the patient, medical his-
tory, clinical examinations, and careful interpretation of
laboratory test results and radiologic findings (6, 7). In-
deed, diagnosis of brucellosis is frequently delayed and of-
ten missed especially in the developing countries (8). The
gold standard for diagnosis still is bacterial culture, which
often fails. Thus, diagnosis relies on the combination of
several methods (9).The present study aimed at reviewing
laboratory tests in the diagnosis of brucellosis.
2. Evidence Acquisition
In the current review, data were retrieved by search
in MEDLINE (via PubMed), Web of Science, Embase, and
Cochrane databases, as well as references of the related ar-
ticles. The following search keywords were used with the
help of Boolean operators (AND or OR): Brucella, brucel-
losis, human, and diagnosis. Articles published from 1953
to December 2018 were included. Inclusion criterion was
articles using the following techniques and/or methods:
direct isolation and identification, conventional cultural
examinations, lysis-centrifugation, blood clot culture, au-
tomated and semi-automated techniques, serological di-
agnostic tests, and molecular assays. After screening the
abstracts in terms of applied techniques and methods, in-
formation was extracted from selected articles in terms of
microbiological, serological, and molecular techniques.
3. Results
Diagnostic approaches for human brucellosis are pre-
sented in Figure 1. Comparison of different diagnostic
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methods for human brucellosis is described in Table 1.
3.1. Direct Isolation and Identification
The isolation of Brucella spp. is considered as the gold
standard technique for the diagnosis of brucellosis. The
culture of Brucella is specific and allows definitive identifi-
cation and typing of the isolates of Brucella spp. that is par-
ticularly valuable for epidemiological investigations (10).
Sensitivity of the Brucella spp. isolation is variable depend-
ing on the culture method, type of clinical sample, stage
of the disease, and history of antibiotic use (11, 12). The
risk of acquiring an infection from laboratory ranges 40%
to 100% and depends on various factors; e. g., exposures
due to laboratory accidents and aerosolization of microor-
ganisms during routine identification activities (13). The
ability to direct isolation and culture of Brucella spp. can
vary between acute and chronic manifestations. Although
50% - 80% of acute cases yield positive blood cultures, only
5% of chronic cases are culture-positive (12). In order to
increase the sensitivity, multiple blood sampling should
be conducted in the acute phase of brucellosis (14). The
frequency of bacteremia episodes is another factor, which
should be considered in terms of the time, frequency, and
volume of blood collected for culturing. Use of bone mar-
row aspirate is more sensitive in patients who underwent
antibiotic therapy, as well as the ones with a chronic form
of brucellosis (15).
3.2. Conventional Culture Examinations
There are numerous available culture media in solid,
broth, or biphasic forms for growing Brucella spp. isolated.
Biphasic media such as the Castaneda blood culture bot-
tles, SEPTI-CHEK™ blood culture (BD BBL®), and Hemoline
performance diphasic medium (bioMerieux®) can be used
to avoid subculture (15, 16). Commercially available bio-
chemical tests such as API 20 NE® (bioMérieux®) are par-
ticularly useful for the rapid and easy identification.
3.3. Lysis-Centrifugation
LC technique is used to concentrate intracellular Bru-
cella spp. in blood samples and consequently, increase the
test sensitivity (17). The sensitivity, specificity, and positive
and negative predictive values of the LC method are 100%,
87.8%, 81.6%, and 100%, respectively compared with those of
the Castañeda method (17).
3.4. Blood Clot Culture
Clot culture is a more suitable choice when a second
blood sample is not available. Since clot culture techniques
are sensitive, simple, and inexpensive and yield earlier re-
sults, they can be settled in the areas where automated
systems are far from reach. The overall mean time-to-
detection of clot culture technique is approximately four
days less than that of the conventional methods (18).
3.5. Automated and Semi-Automated Techniques
BACTEC™ (Becton Dickinson Diagnostic Systems®),
and BacT/ALERT™ (bioMérieux®) are two frequently used
systems in many laboratories that continuously moni-
tor the growth of microorganisms by labeled CO2. The
BACTEC™ Myco/F-Lytic system (Becton Dickinson Diagnos-
tic Systems®) is also developed to improve the recovery
rate of intracellular pathogens such as Brucella spp. by
combined lytic activity and automation (19). Recently,
the Micronaut™ semi-automated biotyping System (Mer-
lin Diagnostika®), which facilitates the metabolization of
various substrates by bacterial cells, was used for the iden-
tification of Brucella species and biovars (20).
3.6. Serological Diagnostic Tests
The serological diagnosis of brucellosis commonly re-
lies on the confirmation of the rising titters of Brucella-
specific antibodies. This is the indirect proof of infec-
tion. Serological assays are used for the primary diagno-
sis of infection, as well as treatment follow-up (21) (Table
1). Immunoglobulin (Ig) M isotype antibodies against the
lipopolysaccharide (LPS) of Brucella spp. are the first im-
munoglobulins emerge after infection and are the pre-
dominant antibodies during the acute phase of the disease
(22). The presence of specific IgM is considered suggestive
of acute or recent infection. But, IgM antibody detection
in the absence of IgG may lead to a misdiagnosis of acute
brucellosis and may be a source of controversy (23, 24).
However, the early IgM response might not be seen in pa-
tients infected with slow-onset strains, as well as in those
appeared late in the course of the disease, or in those with
relapses.
The titer of antibody should decline after an effective
treatment. Otherwise, the patient should be examined for
the possibility of chronic focal disease or relapse. Further-
more, the significant titers of antibody may persist for sev-
eral months or even years in patients with the history of
brucellosis. False positives in the determination of anti-
Brucella IgM may be due to the presence of cross-reactions
and rheumatoid factor. It may be difficult to distinguish
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Table 1. Comparison of Different Diagnostic Methods for Human Brucellosis
Method Advantage Disadvantage
Conventional culture Gold standard and specificity Time consuming, insensitive or low sensitive, and posing
a risk for laboratory staff
BACTEC™ and BacT/ALERT™ Rapid, sensitive, and limiting exposure to infectious
agents
Costly, and need of subsequent identification
Serum agglutination test Safe, inexpensive, and appropriate for primary screening Cross-reactivity with other microorganisms,
false-negative results in the early stages of infection, and
prozone phenomenon
2-Mercaptoethano A confirmatory test that allows selective quantification of
IgG anti-Brucella
Toxicity of mercaptoethanol, the possibility of IgG
degradation by the 2-ME, which may lead to false
negative results
Coombs antiglobulin agglutination test Sensitive for relapsing and chronic brucellosis Labor-intensive and time consuming
Rose Bengal plate agglutination test Rapid for primary screening, simple, and inexpensive Cross-reactivity with the antibodies of other
microorganisms, false-negative results in the early stages
of infection, and prozone phenomenon
Complement fixation test Sensitive and specific Complexity, high prices of reagents, need of trained
laboratory technicians, and expensive equipment
ELISA Highly sensitive and specific, rapid, simple, and capable
of distinguishing between acute and chronic stages
Cross-reactivity
Fluorescence polarization immunoassay Highly sensitive and specific, and capable of
distinguishing between acute and chronic stages
Costly, need of trained laboratory technicians, and
expensive equipment
Lateral flow assay Easy, rapid, sensitive, and specific Expensive and possibility of cross-reactivity
PCR Rapid and accurate; can be performed on blood, serum,
CSF, and other clinical samples; can yield positive results
as early as 10 days after inoculation
Expensive equipment, genus specific Brucladder has low
detection limit, and works only on pure cultures
Real-time PCR Highly sensitive, specific, and rapid; can be performed on
blood, serum, CSF and other clinical samples
Expensive equipment
MALDI-TOF MS Highly sensitive and specific; can be performed on blood,
serum, CSF, and other clinical samples
Expensive equipment
Immunoblot Sensitive and specific Cross-reactivity
NGS Specific technique Expensive equipment; need of software and complicated
analysis
between active infection and simply exposure to the bacte-
ria without clinical relevance in endemic regions by sero-
logical methods (25, 26).
3.7. Fluorescence Polarization Immunoassay
Fluorescence polarization immunoassay utilizes
molecular rotation, measuring antigen-antibody binding
without the need for separation procedures. It requires
one-step serum dilution, assessment of background flu-
orescence, addition of the labelled antigen, and finally
measurement of antigen-antibody interaction (27). The
accuracy of the FPA is equal or superior to other sero-
logical assays such as the complement fixation test (CFT)
or the enzyme-linked immunosorbent assay (ELISA). The
specificity and sensitivity of FPA for culture-confirmed
human brucellosis is 98% and 96%, respectively (12, 28).
3.8. Immunochromatographic Lateral Flow Assay
Immunochromatographic lateral flow assay is a sim-
plified version of the ELISA for the detection of Brucella-
specific IgM and IgG antibodies (22). Immunochromato-
graphic lateral flow assay is capable of identifying acute,
persistent, and relapsing infections. It can also be used to
monitor treatment. The sensitivity and specificity of ILFA
to detect Brucella IgM and IgG in comparison with ELISA
or CFT reported 96% and 99%, respectively (22). Therefore,
ILFA for both Brucella IGM and IgG antibodies is a suitable
method for endemic areas with limited resources (29).
3.9. Molecular Assays
Molecular methods become valuable tools for clini-
cal diagnosis and public health surveillance purposes, as
well as identification of species and subspecies (30). These
techniques can be more sensitive than blood culture and
more specific than serologic tests. Molecular assays can be
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• Patient's epidemiological and occupational history 
   (consuming unpasteurizded/raw dairy products, direct contact with 
   infected animals, laboratory personnel, slaughterhouse workers, 
   meat handler, veterinarians, traveling to endemic areas). 
• Clinical symptoms and sipxs (undulant fever, arthralgia or 
    arthritis, anorexia, asthenia fatigue, weakness, malise, 
    hepatomegaly, and splenomegaly). 
• Hematological and biochemical testing. 
• Radiological examination. 
                              Direct isolation of Brucella *
• Culture of blood or bone marrow during a fever episode 
    and CSF, liver or spleen biopsy in focal complicatioas. 
• Using biphasic media (Castaneda bottles, SEPTI- 
   CHEKTM Blood Culture, and Hemoline Performance 
   Diphasic Medium). 
• Using automated techniques (BACTECTM  Myco/F-Lytic 
    system or BacT/ALERTTM ) 
            Identification of isolares 
• Conventional biochemical methods 
• Agglutination methods using povalent 
   and monospecific antisera 
                          Molecular approaches 
• Standard PCR using the genus-specific primers (B4/B5, 
   JPF/JPR, p1/P2, F4/R2) 
• Multiplex PCR for identificadon of Brucella species 
   (AMOS and Bruce-ladder approaches) 
• Real-time PCR  Assays (targeting the bcsp31 to screen for 
   Brucella genus and IS711 for species identification) 
Appropriate Antibiotic 
Therapy 
                                     Serological tests 
Primaty screening tests (RBT/SAT/ BPA/ BMAT) 
Confirmatory tests (CAT/ CFT/ ELISA/ Brucella Capt/
FPA)
Evaluating Stage of disease (SAT and CAT/ELISA-IgM
and-IgG) 
RBT+/or BPA+/ or BMAT>1:160 and or CAT>1:160/ or ELISA>1:160/ or Brucella Cap>1:160 **
Treatment follow-up
+ +
+
+
+
+
+/-
-
Figure 1. Diagnostic approaches for human brucellosis. * Direct isolation of Brucella needs BSL-3 laboratory capability. ** In endemic areas, high titers (cutoff points) may
be considered as a positive reaction. BMAT, Brucella microagglutination test; BPA, buffered plate antigen test; CAT, Coombs antiglobulin agglutination test; CFT, complement
fixation test; CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; FPA, fluorescence polarization immunoassay; SAT, serum agglutination tube test.
performed on various clinical samples including serum,
whole blood, cerebrospinal fluid (CSF), synovial or pleu-
ral fluid, urine, and even tissue specimens. Furthermore,
they can supplement phenotypic tests (31, 32). However,
direct detection of Brucella DNA in patients suspected of
brucellosis may be a challenge due to the small number
of circulating bacteria in the blood, especially in chronic
courses or after antibiotic therapy. Moreover, the detec-
tion of Brucella DNA cannot demonstrate an active infec-
tion with viable pathogens, and thus, may not efficiently
support the therapeutic decision making. The type of clin-
ical sample, the DNA extraction method, the specific gene
that is tracked, and the employed technique are factors
that can influence the efficiency of molecular assays (33).
3.10. Standard Polymerase Chain Reaction
PCR can be performed to amplify and detect Brucella
DNA in clinical samples or pure cultures. Previously,
Navarro et al. described several advantages of using serum
samples for nucleic acid amplification (34). Several single-
step PCR assays are developed to amplify and detect spe-
cific genomic sequences of the genus, species, or even bio-
types of Brucella. Primer pairs used to detect Brucella at
the genus-specific level include the primers for sequences
encoding BCSP31 (B4/B5), 16SrRNA (F4/R2), 16S - 23S inter-
genic transcribed spacers (16S - 23S ITS) (Bru ITS-S/Bru ITS-A),
16S - 23S rDNA interspace (ITS66/ITS279), IS711 (IS313/IS639),
outer membrane proteins (omp2b, omp2a and omp31), per
(bruc1/bruc5), and proteins of the omp25/omp31 family of
Brucella (35-38). Specificity and sensitivity of these tech-
niques vary depending on the sets of primers, type of clin-
ical sample, and presence of human genomic DNA (Table
2).
B4/B5 primers targeting bcsp31 are often used for the
detection of eukaryotic brucellosis in clinical settings. This
primer pair has the highest sensitivity (> 98%) in testing
buffy coat or whole blood samples (40). Four primer pairs
including B4/B5, JPF/JPR, P1/P2, 26A/26B, and F4/R2 can be
applied in four distinct PCR assays to detect B. abortus, B.
melitensis, B. suis, and B. canis at the genus level. These as-
says are ideal for rapid confirmation of human brucellosis
(41). Two multiplex PCR assays, called AMOS and Bruce-
ladder, are standardized and used to detect Brucella strains
of animal or human origin (42). A multiplex PCR assay was
described by Kumar et al. for the simultaneous detection
of B. melitensis, B. abortus, and B. suis (43). Researchers re-
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Table 2. Comparison of Different PCR Techniques for the Identification of Human Brucellosis
PCR
Technique
Primer
Name
Primer Sequence Amplicon
Size, bp
Annealing
Temp, °C
No. of
cycles
Specificity,
%
Sensitivity,
%
PPN, % NPN, % Detection
Limit, fg
Reference
bcsp31a
B4 TGGCTCGGTTGCCAATATCAA
223 60 40
Bc: 100; Wb:
100; S: 100
Bc: 100; Wb:
100; S: 97
Bc: 100; Wb:
100; S: 100
Bc: 100; Wb:
98; S: 94.3
10 - 100 (39)
B5 CGCGCTTGCCTTTCAGGTCTG
omp2b
JPF GCGCTCAGGCTGCCGACGCAA
193 58 35
Bc: 100; Wb:
100; S: 100
Bc: 100; Wb:
98; S: 95.5
Bc: 100; Wb:
100; S: 100
Bc: 100; Wb:
96.1; S: 91.7
25 - 250 (39)
JPR ACCAGCCATTGCGGTCGGTA
omp2
P1 TGGAGGTCAGAAATGAAC
282 50 30
Bc: 100; Wb:
100; S: 100
Bc: 100; Wb:
99; S: 97
Bc: 100; Wb:
100; S: 100
Bc: 100; Wb:
98; S: 94.3
12.5 - 125 (39)
P2 GAGTGCGAAACGAGCGC
bp26c
26A GCCCCTGACATAACCCGCTT
1029 58 30
Bc: 100; Wb:
100; S: 100
Bc: 100; Wb:
98.5; S: 96.5
Bc: 100; Wb:
100; S: 100
Bc: 100; Wb:
97.1; S: 93.5
20 - 200 (39)
26B GAGCGTGACATTTGCCGATA
16srRNA
gene
F4 TCGAGCGCCCGCAAGGGG
905 54 35 Bc: -
d ; Wb:
100; S: -
Bc: -; Wb:
53.1; S: -
Bc: -; Wb:
53.1; S: -
Bc: -; Wb:
100; S: -
210000 (38)
R2 AACCATAGTGTCTCCACTAA
Abbreviations: Bc, buffy coat; NPN, negative predictive number; PPN, positive predictive number; S, serum; Wb, whole blood.
a Encoding an immunogenic 31-kDa outer membrane protein, which is highly conserved with each known Brucella species and biovar (except B. ovis).
b Encoding a 26-kDa outer membrane protein of Brucella spp.
c Encoding a Brucella immunodominant antigen, named BP26, CP28, or Omp28 protein.
d Undetermined.
ported various procedures that can detect and distinguish
Brucella spp. in human serum and blood samples via a sim-
ple and robust multiplex PCR approach (44-46).
3.11. Other PCR-Based Approaches
Several nested and semi-nested PCR assays were devel-
oped to detect Brucella spp. in human blood samples (47). A
nested-PCR assay was described for the diagnosis of relapse
or chronic brucellosis in clinical practice (48). Both sen-
sitivity and specificity was 100%. A semi-nested PCR assay
for bcsp31 and IS6501 was evaluated on whole blood sam-
ples (49). However, these assays may increase the proba-
bility for primer-dimer formation and/or nonspecific am-
plification products. Moreover, the reported nested-PCRs
can only detect a set of Brucella strains, but not single
species. A novel loop-mediated isothermal amplification
assay (LAMP) was developed to detect Brucella spp. DNA in
human blood samples. The LAMP assay, based on the se-
quence of the highly repetitive omp25 gene, can detect 9
femtogram (fg)/µL of Brucella DNA with a sensitivity of 10
times higher than that of the nested-PCR (50).
Considering its advantages as simple operation, rapid
amplification, and easy detection, the LAMP has potential
applications for clinical diagnosis besides surveillance of
human brucellosis in the developing countries without
requiring sophisticated equipment or skilled personnel.
An inexpensive and simple device such as a water bath
or a heat block that can provide a constant temperature
of 63°C is sufficient and, unlike conventional PCR result,
it can be readout by the naked eye without the need for
electrophoretic analysis (29). An arbitrarily primed-PCR
(AP-PCR) to detect and identify 25 different Brucella strains
is also introduced (51). Some PCR-restriction fragment
length polymorphism (PCR-RFLP) techniques are success-
fully used to distinguish Brucella species and various bio-
vars.
Restriction maps of omp2a and omp2b genes showed
a greater diversity among and within Brucella spp. than
other genes investigated so far. PCR-RFLP assays may serve
as tools for diagnostic and epidemiological surveillance
purposes (52). Furthermore, a PCR-enzyme immunoassay
(EIA) was used by Vrioni for the diagnosis of human brucel-
losis directly from peripheral blood. Following the amplifi-
cation of the bcsp31 target sequence, the amplified product
was detected in a hybrid well-microtiter plate by hybridiza-
tion analysis. The diagnostic specificity of the PCR-EIA for
both whole blood and serum specimens was 100%, whereas
the sensitivity was 81.5% for whole blood specimens and
79% for serum specimens. Vrioni et al. recommend that the
detection of Brucella DNA in whole blood and serum spec-
imens by PCR-EIA, as a sensitive and specific method, can
help the rapid and accurate diagnosis of acute brucellosis
(53)
3.12. Real-Time PCR Assay
The real-time PCR technique is more sensitive, specific,
reproducible, and rapid than the conventional PCR. The
quantitative real-time (qRT)-PCR allows both detection and
quantification of the PCR product in real-time, while it is
synthesized (54). Real-time PCR can be used for the rapid
diagnosis of chronic, but serologically positive, brucellosis
and acute brucellosis when serum and blood samples of
known clinical presentations are investigated (40). These
assays are developed targeting the 16S - 23S ITS region, IS711
element, and omp25, omp31, and bcsp31 genes (55-58). The
bcsp31 gene target can be recommended for the detection
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of bacteria at the genus level. Species-specific identifica-
tion confirming the primary diagnosis by a second gene
target such as IS711 can be done (59, 60). Several multiplex
real-time PCR approaches are developed for the simultane-
ous detection of Brucella spp. and Mycobacterium tubercu-
losis complex (MTC). These techniques amplify the bcsp31,
IS711, and omp2a genes for the detection of Brucella spp. and
target the senX3-regX3, IS6110, and cfp31 genes for the iden-
tification of the MTC (31, 32). Sanjuan-Jimenez et al. eval-
uated three molecular targets (IS711, bcsp31, and omp2a) of
Brucella and three targets of MTC (IS6110, cfp31, and senX3-
regX3) for their simultaneous detection by a multiplex real-
time PCR (61).
3.13. Single Nucleotide Polymorphisms Typing
Some investigators previously described unique real-
time PCR assays that can characterize Brucella isolates to
the species level. They used single nucleotide polymor-
phisms (SNPs) multilocus sequencing (62). Foster et al. ap-
plied SNPs to housekeeping genes and introduced gene se-
quences that can identify the seven main Brucella species
using the TaqMan assays with contained probes specific to
each allele. The assays can detect DNA concentrations of
less than 10 fg/mL that is their detection limit (63). How-
ever, finding SNPs that can separate B. canis from B. suis is
challenging due to a high degree of sequence homology
that indicates a recent split between these species (63).
3.14. Multilocus Variable Number of Tandem Repeats Analysis
PCR methods can detect Brucella spp. based on the find-
ing of specific sequences, but limits of these techniques,
for example, failure to differentiate among biovars within
a species, encouraged the development of other molecu-
lar typing methods such as multilocus variable number of
tandem repeats analysis (MLVA). Multilocus variable num-
ber of tandem repeats analysis measures the number of
tandem repeats at a specified locus and can discriminate
between isolates within a certain Brucella biovar. The MLVA
is a quick and efficient method for typing and cluster-
ing Brucella strains. Moreover, multilocus sequence typing
(MLST), sequencing of multiple genetic loci in bacteria, is
increasingly accepted as a mean for the classification of mi-
crobial populations (64).
3.15. Matrix-Assisted Laser Desorption Ionization
The time of flight mass spectrometry (MALDI-TOF MS) is
used as a fast and reliable technique for bacterial identifi-
cation based on protein profile characteristics of microor-
ganisms (65). MALDI-TOF MS is a reliable test for direct de-
tection of Brucella to the genus level from blood culture
bottles and culture plates. However, Brucella has not been
yet incorporated into some of the main available databases
due to its potential bioterrorism application (66). Another
limitation of MALDI-TOF MS to detect Brucella is the need
for pure cultures, which pose health hazards to laboratory
personnel. Mesureur et al. described a simple and safe
method for inactivation of Brucella isolates prior to their
analysis by MALDI-TOF MS (67).
3.16. Novel Technologies for the Serologic Diagnosis of Brucel-
losis
The immunoblot-based assay showed several immun-
odominant proteins of B. abortus and B. melitensis in a pre-
vious study; this technique can be used to identify new
candidate antigens for the serologic detection of brucel-
losis (68). Immunoproteomics of B. abortus RB51 (a mu-
tant strain lacking the LPS portion) revealed several candi-
date antigens. The highly immunogenic proteins may be
useful as alternative antigens to avoid cross-reactivity (69).
Immunoproteomics of B. abortus also showed differential
antibody profiles for B. abortus strain, S19-vaccinated and
naturally infected cattle, and differentiation between vac-
cinated cattle and those animals infected with field strains
(70).
4. Conclusions
Laboratory diagnosis of brucellosis still relies upon
culture of bacteria followed by various biochemical and
serological test results. Nucleic acid tests such as PCR are
the novel-generation technologies that have higher sensi-
tivity than blood cultures and better specificity than sero-
logic tests. Molecular techniques such as PCR facilitate
rapid, sensitive, and specific detection. MLVA is helpful for
following an infection. Finally, it should be emphasized
that novel technologies such as microfluidic lab-on-chip
and next-generation sequencing (NGS) can provide a rapid,
accurate, and safe diagnosis of brucellosis, especially in en-
demic countries. Future research on immunoproteomics
and the selection of highly immunogenic protein spots
can be useful as alternative antigens for the diagnosis of
brucellosis.
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